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Introduction
The family Picornaviridae is a large and diverse group of positive sense RNA viruses, which consists of several important human and animal pathogens. The family contains 26 genera including the Enterovirus and Parechovirus genera. The genus Enterovirus contains over 250 recognized types that can infect humans, including poliovirus (PV), echovirus (E), coxsackie-A and B viruses (CVA and CBV) and rhinovirus (RV), while the species Parechovirus presently contains 16 recognized genotypes (1) (2) (3) (4) (5) (6) (7) (8) . HEV and HPeV infections are common in young children and adults causing a broad range of disease, including gastrointestinal and respiratory tract infections, aseptic meningitis, paralysis, myocarditis and neonatal sepsis. HEV and HPeV infections can be severe and life threatening, while no antiviral treatment is available. Presence of maternal antibodies (Abs) and Abs transferred during breast feeding play an important role in protection of neonates against picornavirus infection. For HEV it has been shown that in neonates with severe HEV infection, the absence of maternal virusspecific neutralizing Ab titers is correlated with disease, suggesting HEV specific neutralizing Abs are important for protection (9) . In neonates with severe HEV infection intravenous immunoglobulins (IVIg) is given as supportive treatment, but high serotype specific Ab titers are needed, which can vary between IVIg batches (10) . Therefore, treatment against HPeV viral infections with specific monoclonal antibody (mAb) would be a good option. mAbs are highly specific and normally well accepted by the host. These Abs currently do not exist for HPeV and HEVs but with new approaches to rapidly generate human mAbs, as has been shown for influenza viruses (11) and respiratory syncytial virus (12, 13) , this should be feasible. Since infections with HEVs are transient and humoral immunity is responsible for clearing the virus, new vaccination strategies should focus on eliciting neutralizing Abs. For poliovirus very effective vaccines were developed in the 1950s inducing humoral immunity, which prevent viraemia and disease. However the neutralizing Abs against one serotype did not protect against infection with the other serotypes, therefore vaccines had to contain single strains of each serotype (14, 15) . Since the capsid of HEVs consist of 60 protomers constructed out of 4 polypeptides namely VP2, VP4, VP3 and VP1 the neutralizing Ab response is directed against these polypeptides. HEVs major neutralizing antigenic sites reside on the VP1 capsid protein and lesser extent on VP2 and VP3 (16) (17) (18) . In the case of foot and mouth disease (FMDV) virus, another vaccine preventable picornavirus affecting cloven-hoofed animals, a dominant antigenic site is located in the GH loop of the VP1 capsid (19) (20) (21) . Neutralization directed against this epitope is largely serotype specific and cross-reactivity is limited between serotypes, due to broad antigenic variation (22) (23) (24) (25) (26) . Thus, neutralizing Abs against picornaviruses are considered genotype specific and it is assumed that they do not cross-protect against infections with other types. HPeVs show many resemblances to HEVs with respect to clinical manifestations as well as biological features (27) . An important difference is that VP0 is not cleaved into VP4 and VP2 in HPeVs and little is known about humoral immunity against HPeVs. Two studies from Finland show seroprevalence >97% for HPeV1 in adults (28, 29) . In a combined study in Finland and the Netherlands a seroprevalence of neutralizing Abs in adults was high for HPeV1 (>92%), and for HPeV2 (>86%) (30) . Interestingly the response against HPeV2 cannot be explained by circulating HPeV2 virus since it is not detected in these countries. The responses are directed against different antigenic sites in the three different capsid proteins of HPeV namely VP0, VP3, and VP1 (31) . In a study of Alho et al., (32) potent neutralization could be obtained with serum from rabbits vaccinated with HPeV-VP1 protein against VP1, and it was shown that the C-terminal region of VP1 is an important antigenic site. In addition, antiserum elicited against VP0 could partly neutralize HPeV1 infection, showing that the N-terminal region of the VP0 is another antigenic site. While the humoral immune response against HEVs is thought to be type specific, some cross-neutralization has been shown. CVA9 antiserum showed full inhibition of HPeV1 infection in cell culture, and HPeV1 antiserum almost completely blocked CVA9 infectivity. Both viruses contain the arginine-glycine-aspartic acid (RGD) containing C-terminal VP1 polypeptide, and after deletion of the RGD motif in CVA9 this cross neutralization was diminished (32) . HPeV1, HPeV2, 4, 5, and 6 contain a similar RGD motif, and indeed, cross-neutralization has been reported with polyclonal Abs against these viruses (33) . Since the absence of neutralizing Abs is a risk factor for severe disease in infants, prophylactic and possible therapeutic treatment of picornavirus infections with mAbs would be a logical option. The accessibility of different antigenic sites, and the observed cross reactivity makes the small group of HPeVs a good target for development of therapeutic human mAbs. In this paper, we describe the characteristics of one polyclonal, and two novel HPeV1 crossneutralizing human mAbs.
Material and Methods

Virus culture and purification
HPeV1-Harris and the HPeV2-2008 strains were provided by the Dutch National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, the primary strains HPeV3-150237, HPeV4-251176, HPeV5-552322 and HPeV6-550389 were obtained in house (34, 35) . For testing cross neutralization the following HEV strains were used: EV71, CVB3, RVA16, CVA9-AMC, CVA9-1051883, CVA-1052186, E9-1252784, and E9-Barty. The RGD-containing E9-Barty strain was a kind gift from Prof. F. van Kuppeveld (Department of Virology at the Faculty of Veterinary Medicine, University of Utrecht). For virus culture of HPeV1, 2, 4, 5, and 6, CVA9 and the E9 strains the human colon carcinoma (HT29) was used, HPeV3 was cultured on African green monkey kidney (Vero) cells. The cells were maintained in Eagle's Minimum Essential Medium (EMEM) with L-glutamic acid (0.2X), non-essential amino acid (1X), streptomycin (0.1 μg/ml) and ampicillin (0.1 μg/ml), supplemented with 8% heat-inactivated Fetal Calf Serum (FCS). The virus concentration was determined by the median tissue culture infective dose (TCID50) and calculated by the Reed and Muench method (30) . For total virus purification cells were infected with an MOI of 0.1 and after appearance of CPE (cytopathic effect) grade 4+ (75-100% infection) the supernatant and cells were collected and freeze thawed twice (-80°C) then centrifuged at 4000rpm for 15 minutes. After the supernatant was collected and filtered through a 0.22 µm filter, it was centrifuged at 32000rpm, for 2h at 4°C in the ultracentrifuge (rotor SW32Ti, Beckman). The pellet was dissolved in 1xTNM buffer (10mM Tris-HCl, pH 7.5, 150mM NaCL, 1mM MgCl2) and virus was purified on a cesium chloride step gradient made of 40% (w/v) bottom layer, 15% (w/v) top layer by centrifuging at 32000rpm, for 16hrs at 4°C (rotor SW41Ti, Beckman). The fraction containing the virus was harvested and exchanged with TNM buffer and concentrated with 100kDa cutoff filter (Millipore).
Rabbit polyclonal Ab preparation and human monoclonal Ab discovery
Polyclonal Abs were obtained by Rabbit immunization (Harlan Laboratories). The purified virus was used for immunization of one rabbit. The rabbit received 5 times every 14 days a boost of 200μg purified virus and nancy. The final bleed was taken after 77 days. The AM18 and AM28 Abs were obtained from healthy human donors using a direct virus neutralization assay of HPeV1 virus pre-incubated with Ab containing supernatant of cultures with different B cell densities, generated as described previously (12, 13) . In brief, CD27+ memory B cells were isolated from peripheral blood by FACS sorting. Cells were stimulated for 36 hrs with CD40L and interleukin (IL)21 and subsequently transduced with a retrovirus containing the Bcl-6 and Bcl-xL transgenes together with the marker gene GFP. Transduced B cells can be maintained for prolonged periods of time and harbor a Germinal Center phenotype, which is characterized by expression of cell surface immunoglobulin (the B Cell Receptor -BCR-) and secretion of soluble immunoglobulin. Abs present in the supernatant can be tested for binding to specific antigens or tested in direct functional assays. Here we tested the HPeV1 neutralizing capacity of Abs in B cell supernatants by co-incubation of supernatants with virus (at 100TCID50/ 50μl and 20TCID50/ 50μl) for 1 hr before they were added to HT29 cells. Infection was determined by read out of CPE. Cultures that blocked CPE formation were single cell subcloned to obtain monoclonal B cell cultures. The Ab heavy and light chain genes were retrieved from these B cell clones and expressed as recombinant protein in 293T cells. IgG1 Abs were subsequently purified using HiTrap Protein A columns on an ÄKTA instrument (GE).
Virus neutralization assay
To determine neutralizing potency the AM18 and AM28 Abs were tested in an endpoint neutralization assay starting at 25μg/ml. Abs were mixed with HPeV1 virus suspension containing 100 TCID50/50μl. Mixtures were incubated at 37°C for 1hr before inoculation of HT29 cells in a 96-wells plate (200 μl). As positive control, cells were inoculated with 100TCID50 with an irrelevant Ab and without Abs. As negative controls only Abs or only medium was added to the cells. The cells were examined for the appearance of CPE every 24h for 7 days. At day 7, 25μl of supernatant was removed for RNA isolation using the total nucleic acid isolation kit with the MagnaPure LC instrument® (Roche Diagnostics). The RNA was eluted in 50μl elution buffer and reverse transcribed as previously described (34) . Five μl of cDNA was used for to estimate viral copy number using LC480® real time PCR machine (Roche Diagnostics). The virus copies per PCR were calculated with a standard curve as previously described (36) .
Expression and purification of HPeV capsid proteins
To generate recombinant capsid protein VP0, VP3 and VP1 from the HPeV1-Harris cDNA strain and the virus isolates HPeV2, 3, 4 primer sequences were used as depicted in Table  S1 , using the following PCR: 5' 95°C, followed by 35 cycles 30s at 95°C, 30s at 55°C and 60s at 72°C and an extension step of 10' at 72°C. The purified PCR fragments were cloned into the expression vector Pet102 with his-tag and expressed in Escherichia coli BL21 Star™(DE3) One Shot® cells. Single bacterial colony was inoculated in LB medium supplemented with 100 μg/ml ampicillin and propagated at 37°C with 220rpm speed on a shaker incubator untill the culture reached logarithmic growth phase (at OD600 0.6-0.7). To stimulated recombinant protein expression 0.5mM isopropyl β-D-thiogalactopyranoside (IPTG) was added to the cultures. The proteins were purified by using Ni-NTA purification system with Anti-His(C-term)-HRP Ab in accordance with the manufacturer's instructions (K953-01, Invitrogen).
ELISA
ELISA plates were coated with 200ng of purified HPeV1-6, or the different capsid proteins VP0, VP3, VP1 from HPeV1-4 overnight at room temperature (RT). After washing with 0.1%tween/PBS (3 times) the protein coated ELISA plates were blocked with 2% BSA in PBS for 2 hrs at room temperature. The plate was incubated with 2 µg/ml of aHPeV1 AM18 or AM28 for 1 hr at RT and washed 3 times with PBS/0.1% Tween. Anti-human or anti-rabbit IgG, HRP labeled (0.3 µg/ml) was used as the secondary Ab, incubated for 1 hr at RT and washed three times with PBS/0.1% Tween. The substrate solution containing 3,3' ,5,5'-tetramethylbenzidine was added and incubated for 10min at RT in the dark. The reaction was stopped by the addition of 0.8 M H2SO4. The O.D. at 450nm and 620nm was measured with a microplate reader.
Western blot
The whole virus and purified capsid proteins VP0, VP3 and VP1 were run on 10% sodium dodecyl sulphate polyacrylamide gel electropheresis (SDS-PAGE) in duplicate. One gel was stained with coomassie brilliant blue R/G and the other was used for western blotting using semi dry blotting at 15V for 15 min on a nitrocellulose membrane. The membrane was blocked overnight at room temperature (RT) with 5% donkey serum in PBS. HPeV1 specific mAbs AM18 and AM28 were diluted in washing buffer, containing 1% donkey serum in 0.1% Tween20/PBS and added to the membrane. The membrane was washed 3 times for 5 min each, and incubated with anti-human IgG Alexa 486 (1:5000 dilution) in washing buffer for 1hr at RT. The membrane was washed 3 times and scanned with the Odyssey infrared imaging system (LI-COR, biosciences).
Immunofluorescence assay
The immunofluorescence was performed as described previously (33) . In brief, HT29 cells were incubated with the primary Abs AM18 (2 μg/ml) and AM28 (2 μg/ml). As secondary Ab 15 μg/ml of goat anti-human IgG-Alexa 488 was used and the nuclei was stained with 0.5 μg/ml 4' ,6-diamidino-2-phenylindole (DAPI) (Sigma).
Results
Generation of HPeV1 neutralizing mAbs
Human memory CD27+IgG+ B cells were obtained from peripheral blood from three healthy donors and were transduced with Bcl-6 and Bcl-xL and cultured at 50 cells per well in 96 well plates before they were frozen at -150°C in a 96 well plate format. The corresponding B cell culture supernatants were also frozen thereby creating a B cell and culture supernatant biobank. The supernatants were tested for direct neutralization of 100 and 20TCID50 of HPeV1 in a HT29 cell rounding assay at the appropriate time. From the cultures that showed reduced cell rounding at both TCID50s, single B cell cultures were generated to retrieve the original monoclonal B cell. From clones that showed repetitive neutralization of HPeV1, RNA was isolated to retrieve the Ab heavy and light chain sequences (Table 1 , Supplementary Table 1 ). These sequences were used to generate recombinant protein from 293T cells. Ab AM18 (original clone 18E10, VH1-3) and AM28 (original clone 28G3, VH3-23) were both of the IgG1 isotype and both contained a Kappa light chain. The B cells presumable have gone through multiple rounds of selection and somatic hypermutation since the VH contained up to 22 amino acid substitutions for AM18 and 16 for AM28. In addition to the VH chain, selection has also been imposed on the light chain with 6 amino acid substitutions in each. Based on the completely different VH and VL gene usage the B cell clones do not seem to be related. 
Cross reactivity of HPeV1 specific polyclonal and human mAbs between HPeVs
The polyclonal rabbit Ab aHPeV1-HARLAN and the monoclonal Abs AM18 and AM28 both neutralizing HPeV1, were tested for binding to HPeV1 to 6 viral proteins in infected cells, by immunofluorescence. All Abs showed specific binding to HPeV1 and HPeV2. In addition, the aHPeV1-HARLAN and AM18 Ab were specifically recognizing cells infected with HPeV4, 5 or 6 ( Figure 1) . None of the mAbs did bound to HPeV3-or non-infected cells. To identify capsid protein specificity, an ELISA was performed with whole purified virus and the different recombinant capsid proteins of HPeV1. The aHPeV1-HARLAN polyclonal Ab mixture showed binding to all the genotypes and recognized the capsid proteins VP0 and VP1 of HPeV1-4. AM18 showed binding to whole purified virus of HPeV1, 2, 4, 5, and 6, and showed binding to the (denatured) VP1 protein of HPeV1, 2, and 4 ( Table 2 ). As shown in the immunofluorescence assay the AM28 Ab recognized HPeV1 and HPeV2 whole purified virus, but did not recognize any of the capsid proteins by ELISA ( Table 2) . All these data were confirmed by western blot (data not shown). 
Ab neutralization of HPeV1 to 6
The HPeV1 Abs were tested for neutralization capacity in vitro against 100TCID50 of HPeV1 to 6 by monitoring inhibition of CPE as well as decrease in copy number by real time PCR (Figure 2, 3, 4) . The HPeV1 Ab AM18 strongly neutralized the HPeV1-Harris and HPeV1B strains at IC50 values of 5 ng/ml (Table 3, Figure 3 ). The HPeV1 Ab AM28 neutralized the HPeV1-Harris and HPeV1B strain even better at IC50 values of 3 ng/ml (Table 3, Figure  4 ). In addition, both Abs showed strong cross-neutralization against HPeV2 ranging from 32-78 ng/ml (Table 3 , Figure 3, 4) . In addition the polyclonal and the monoclonal AM18 Ab but not AM28 could neutralize HPeV4, 5 and 6 at concentrations ranging from 295-555 ng/ ml respectively (Table 3 , Figure 3, 4, 5) . No cross-reaction in binding or neutralization with HPeV3 was observed. 
Ab cross reactivity with HEVs
To test whether the aHPeV mAbs were genus-specific only, both mAb AM18 and AM28 were tested for neutralization of other HEVs. The AM18 and AM28 did not neutralize the non RGD-containing HEVs EV71, CVB3, or RVA16. However, since cross reactivity of polyclonal HPeV1 Abs with the RGD-containing CVA9 has been reported (15) , AM18 and AM28 specificity to different CVA9 strains (CVA9-AMC, and clinical strains 1051883, 1052186) as well as an RGD-containing (E9-Barty) and a non-RGD containing E9 strain (clinical strain 1252784) was tested with an immunofluorescent assay and standard neutralization assays. AM18 was specifically recognizing all three RGD-containing CVA9 strains, although weakly CVA9-1052186 ( Figure 5 ). Similar results were obtained in the neutralization assays, where the CVA9 prototype was neutralized at an IC50 of 118 ng/ml and an IC50 of 63 ng/ml was found for the clinical isolate 1051883, while we could not detected Ab induced inhibition of isolate 1052186 ( Figure 6 ). In case of the E9, the non-RGD nor the RGD containing E9 strains were neutralized by AM18 or AM28 (data not shown), although some weak binding could be found for the AM18 with the E9-1252784. The RGD surrounding amino acids could influence Ab binding to the RGD motif, since the sequences show relatively high similarity in the RGD region (Figure 7 ). 
Discussion
In this study we generated two unique HPeV1 monoclonal Abs using stable Ab producing B cells by genetic programming (12, 13) . We showed that both Abs discovered by directly screening for HPeV1 neutralization, also neutralized HPeV2, indicating that HPeV1 and 2 share similar neutralizing epitopes. This high cross-reactivity of both Abs with HPeV2 could explain why high seroprevalence against HPeV2 is found in the Netherlands and Finland (86-99%) (30) , while HPeV2 infections are hardly detected (35, 37, 38) , suggesting cross protection and seroprevalence by HPeV1 Abs. In addition, the HPeV1 specific AM18 Ab also cross-neutralized HPeV4, 5 and 6, but not HPeV3. The epitope of AM18 is located in the VP1 protein since we could detect binding to the recombinant VP1 capsid protein of HPeV1, 2 and 4, but not to the VP0 and VP3 proteins. AM18 is possibly raised against a linear epitope containing the RGD motif, which is well conserved in the genotypes HPeV1, 2, 4, 5, and 6 at the C-terminus of the VP1 capsid protein but also in CVA9, but not in HPeV3. Cross-binding to the RGD motif was shown previously for CVA9 and HPeV1 with polyclonal Abs (31), but it was never thought that this feature could be assigned to a single mAb. The cross-neutralization of the non-HPeV1 genotypes and the EV CVA9 was less efficient, and the RGD-containing E9 strains could not be neutralized, which indicates importance of the RGD surrounding amino acids making the RGD containing motif less accessible for AM18 and/or the total conformation of the VP1 capsid protein differs. In contrast to AM18, we could not specifically determine the target recognized by AM28, which suggests that AM28 is binding to a non-linear, conformation dependent epitope. The AM28 Ab neutralization might block receptor binding, but possibly the Ab may neutralize by inducing conformational changes or interfering with viral uncoating (39) (40) (41) . For characterization of the exact neutralizing epitopes structural studies of the Ab-virus complex are currently ongoing. The development of a protective B cell response against HEVs is presumably achieved by generation of type-specific Abs against the VP1 capsid protein. However since we discovered two cross-reactive Abs next to the general VP1 specific response a more broad and diverse Ab repertoire may exist that could influence serotyping and prevalence studies based on serum binding assays. Furthermore these cross binding and neutralizing Abs may allow for the development of anti-HPeV treatment and may facilitate vaccine development. It should be noted that our monoclonal Abs did not give any cross-reactivity with the HPeV3 genotype, which already has been shown to differ in many aspects from HPeV1, 2, 4, 5 and 6 (reviewed in (27)). Clinically HPeV3 differs from the other HPeV strains since it is infecting younger children and is more often associated with severe disease, suggesting different receptor use as well as different neutralization mechanisms. Thereby the detection of neutralizing Abs against HPeV3 in serum was shown to be difficult (30, 33) , leaving a challenge to find protective HPeV3 mAb in the future.
